N-Acetyl Selank Amidate

Acetylation at the N-terminus and amidation at the C-terminus remove the charged ends that aminopeptidases and carboxypeptidases cleave, extending exposure without changing the active pharmacophore. Everything established for Selank - prolongation of endogenous enkephalin signalling, shifts in GABA-A subunit expression, serotonergic modulation, effects on IL-6 expression - applies mechanistically. The claimed potency advantage is a stability argument, not a receptor-affinity one, and it has never been quantified in a published study.

Targets: Enkephalin-degrading enzymes, GABA-A receptor expression, Serotonergic system

• · Start well below your Selank dose. Roughly a third to a half of the plain-Selank amount is the usual conversion people settle on.

Work out your exact syringe units →

• commonEmotional flattening or reduced drive— The most commonly reported downside, usually from dosing it like plain Selank.
• commonNasal irritation
• uncommonDrowsiness
• uncommonHeadache

• Pregnancy and breastfeeding - no safety data.
• Not a substitute for a medically supervised benzodiazepine taper.

• redundantselank — Same molecule, capped. Pick one.
• synergyn-acetyl-semax-amidate — Duration-matched pair for focus plus calm; the most common modern nootropic peptide stack.

• · No bloodwork established.
• · Track motivation as well as anxiety - the failure mode here is trading anxiety for apathy.

Not approved anywhere; sold as a research chemical.

Mechanistically this is Selank, and there is nothing further to add at the receptor level because nobody has looked. What is worth saying clearly is that the stability argument for capping Selank is weaker than the equivalent argument for Semax, and for a specific reason: the acetyl group goes onto a threonine hydroxyl-bearing residue rather than a methionine, and the free N-terminal threonine of tuftsin is part of what tuftsin receptors recognise. Tuftsin's biological activity is known to be sensitive to N-terminal modification. So there is a real, if unquantified, possibility that acetylating the N-terminus of Selank trades some target engagement for stability. Nobody has run the comparison. The consistent user finding that a third to a half of the Selank dose gives a comparable effect for longer is compatible either with a genuine potency gain from extended exposure, or with a longer-lasting but somewhat weaker molecule that happens to feel similar. Those two possibilities are indistinguishable without a binding assay, and the assay has not been done.

The failure mode here is more specific and more insidious than with the parent. People carry their Selank dose across, get flat and unmotivated within a week, and interpret that as the anxiety treatment working - because reduced drive genuinely does feel like reduced anxiety from the inside. Emotional flattening is listed as the most commonly reported downside of this compound for exactly that reason, and it is dose-transfer in almost every case. Start at 100 mcg no matter what you were running before. The second problem is evidential and worth stating plainly: unlike the acetylated Semax analogue, which at least has a published proteolysis study, this molecule has no primary literature of any kind. Not a PK study, not a binding assay, not a stability paper. Everything is inference from Selank plus general peptide chemistry, and there is a specific technical reason - tuftsin's sensitivity to N-terminal modification - to think the inference might not hold cleanly here. The third is the usual grey-market identity problem, with no reference standard to check a batch against.

1. 100 mcgDays 1-3 — One morning intranasal dose. Hold three days regardless of how little you feel - the point is to find the flatness threshold before you cross it, not to find the effect.
2. 250 mcgDays 4-10 — Most users settle here. A single morning dose covering 8-12 hours is the entire selling point of the modification.
3. 500 mcgWeek 2 onward — Practical ceiling. Optionally split as 250 mcg morning and 250 mcg evening if sleep-onset anxiety is the target. Above this, emotional flattening is the dominant reported effect.

• Enkephalin-degrading enzymes — Never measured for the capped analogue

  Assumed identical to Selank. This is an inference from shared sequence, not a finding.

• GABA-A subunit expression — Not a binding interaction

  Assumed identical to Selank; never demonstrated for this form.

• Tuftsin receptor / immune signalling — Unknown, and specifically uncertain because tuftsin activity is sensitive to N-terminal modification - the exact position that has been acetylated here

  Possibly reduced relative to Selank. Nobody has checked.

20-40 minutes to first effect intranasally, subtle as with the parent. Peak around 1-2 hours. Users consistently report 8-12 hours of effect from one dose versus roughly 4-8 for plain Selank, though there is no measurement behind either figure. Sleep-onset benefit from an evening dose shows within the first few nights. Any antidepressant-like or antiasthenic effect would be expected over 7-14 days by analogy with the parent's clinical data. Emotional flattening, when it appears, typically shows up in week two and resolves within a few days of stopping. Nothing is known past four weeks.

The intended partner is N-Acetyl Semax Amidate, and the pairing is genuinely better designed than the original: both run 8-12 hours from a single morning dose, so you get focus and calm rising and falling together instead of the arousal outlasting the anxiolysis. Dose them separately, minutes apart, into different nostrils - not premixed in one bottle, because you will want to move one and not the other. Do not run this with plain Selank; it is the same pharmacophore twice with no way to know your total. Combining with alcohol is the interaction people actually have and nobody discusses: there is no documented pharmacological conflict, but a compound working through endogenous enkephalin signalling combined with a drug that also engages that system has no safety data at all, and the subjective flatness stacks unpleasantly. As with the parent, this is not a benzodiazepine substitute for anyone physically dependent on one.

Against plain Selank: longer duration, roughly a third to a half the dose, and no evidence of its own at all. The parent has a comparative human trial against a benzodiazepine with a measured mechanism in the same patients. This has user reports. If you want to know whether the Selank pharmacophore does anything for you, and especially if you want to reach the dose range where the human efficacy data actually sits, use plain Selank - reaching clinical-equivalent exposure with the capped version is guesswork. Choose this one if all-day coverage from a single morning dose is the specific problem. Against N-Acetyl Semax Amidate: the opposite arousal direction, matched duration, made to run together. Against an SSRI or buspirone: not comparable on evidence, but no sexual side effects, no weeks-long onset and no discontinuation syndrome. Against a benzodiazepine: no sedation, no cognitive impairment, no dependence - and also no reliability, no dose-response data and no acute rescue capability.

$15–$50/month. A 30 mg vial runs roughly 45-80 USD. At 250 mcg daily that is 120 days of supply, so 15-20 USD per month is typical - the cheapest per-day compound in this class by a wide margin, precisely because the doses are so small. Compare this against the 120-200 USD per month that properly clinical-dosed plain Selank costs, and the economic case for the capped version is stronger than the evidential one.

• ?There is no primary literature on this molecule at all - no pharmacokinetics, no binding data, no stability study, no trial. It is the least-evidenced compound in this class relative to how widely it is used.
• ?N-terminal acetylation sits on the residue tuftsin activity is known to be sensitive to. Whether capping costs target engagement here has never been tested.
• ?The 8-12 hour duration and the one-third-to-one-half dose conversion are both entirely from user reports.
• ?No enkephalinase inhibition has ever been demonstrated for the capped form specifically.
• ?Whether the immune and IL-6 effects inherited from tuftsin survive N-terminal acetylation is unknown.
• ?The molecular weight of 793.0 Da is consistent with acetylation plus amidation of the 751.9 Da parent but I did not verify it against a published characterisation.
• ?No data exists on use beyond four weeks.
• ?Purity and completeness of capping vary by supplier with no reference standard available for comparison.

• Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia Zozulya AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OY, Serebryakova EV, Siranchieva OA, Andryushenko AV, Telesheva ES, Siuniakov SA, Smulevich AB, Myasoedov NF, Seredenin SB, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008 · PMID 18454096

  The parent compound's human trial. Included because it is the only clinical evidence anywhere near this molecule - and because it is evidence for a different molecule, which is the point.

• Study of proteolysis of Semax analogues with different N-terminal amino acids by carboxypeptidases Shevchenko KV, Nagaev IY, Andreeva LA, Alfeeva LY, Myasoedov NF, Doklady Biological Sciences, 2013 · PMID 23821053

  Not about Selank, but it is the best available demonstration that N-terminal chemistry governs degradation rate in this exact peptide family. The chemistry rationale for capping, one molecule over.